Natural killer cells and anti-tumor immunity.
CIS
Cancer
IL-15
ILCs
NK cells
SOCS proteins
SOCS2
Journal
Molecular immunology
ISSN: 1872-9142
Titre abrégé: Mol Immunol
Pays: England
ID NLM: 7905289
Informations de publication
Date de publication:
06 2019
06 2019
Historique:
received:
29
07
2017
revised:
20
11
2017
accepted:
01
12
2017
pubmed:
14
12
2017
medline:
29
10
2019
entrez:
14
12
2017
Statut:
ppublish
Résumé
Immune checkpoint inhibitors harness the power of the immune system to fight cancer. The clinical success achieved with antibodies against the inhibitory T cell receptors PD-1 and CTLA4 has focused attention on the possibility of manipulating other immune cells, in particular those involved in innate immunity. Here we review the role of innate lymphoid cells (ILCs) and their contribution to tumor immunity. As the prototypical ILC, the natural killer (NK) cell has an intrinsic ability to detect and kill cancer cells. NK cells are dependent on the cytokine interleukin (IL)-15 for their development and effector activity. We discuss the role of the Suppressor of cytokine (SOCS) proteins in negatively regulating IL-15 and NK cell responses and the potential for targeting these small intracellular regulators as new immune checkpoints.
Identifiants
pubmed: 29233542
pii: S0161-5890(17)30595-3
doi: 10.1016/j.molimm.2017.12.002
pii:
doi:
Substances chimiques
Suppressor of Cytokine Signaling Proteins
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
40-47Informations de copyright
Copyright © 2017 Elsevier Ltd. All rights reserved.